Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA damage-binding protein 2 (DDB2), also known as the p48 subunit, is a critical component of the UV-damaged DNA-binding (UV-DDB) complex, which initiates the global genome nucleotide excision repair (GG-NER) pathway [1, 8]. It primarily functions as a damage sensor that recognizes ultraviolet-induced DNA lesions, such as cyclobutane pyrimidine dimers and 6-4 photoproducts, and recruits the CUL4A-DDB1 E3 ubiquitin ligase complex to the site of damage [3, 7]. Within this complex, DDB2 acts as a substrate receptor, mediating the ubiquitination of histones and repair factors like XPC to facilitate chromatin remodeling and efficient DNA repair [7, 11]. Beyond its role in NER, DDB2 is involved in regulating the cell cycle, apoptosis, and premature senescence through interactions with p53, p21, and E2F1 [1, 10, 14]. In human health, mutations in the DDB2 gene cause Xeroderma pigmentosum group E (XPE), a condition characterized by extreme sensitivity to sunlight and a high risk of skin cancer [2, 8]. In oncology, DDB2 exhibits a context-dependent role, acting as a tumor suppressor in normal tissues but often contributing to chemoresistance and poor prognosis in established malignancies by enhancing DNA repair capacity [6, 9, 14]. Consequently, DDB2 is an emerging therapeutic target, with strategies such as using lapatinib to disrupt its DNA-binding activity being explored to sensitize tumors to chemotherapy and PARP inhibitors [4, 9].
Disruption of DDB2-DNA interaction, Inhibition of nucleotide excision repair, Chemosensitization, Radiosensitization, Regulation of p53-mediated apoptosis
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA damage-binding protein 2 (DDB2) (DDB2).